GOT2 and hepatocellular carcinoma: Table 3 summarizes how overexpressing (+) or knocking down (−) wild-type or mutant CTNNB1 in hepatocytes affects HCC. Studies led by Satdarshan Monga, Makoto Taketo, and Christine Perret have indicated that the expression of wild-type or activated forms of β-catenin in mouse hepatocytes under control of the Alb (albumin) or Fabp (fatty acid-binding protein) promoter is not enough to drive HCC [71,72,73,74] (Table 3). Similarly, targeting mouse hepatocytes with activated β-catenin by hydrodynamic tail vein injection (HDT) is not sufficient to induce HCC [75,76,77] (Table 3).